Generic Requip Cleared For RLS
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva, Mylan, Roxane and Par will market ropinirole for Restless Legs Syndrome; Parkinson's patent expires this month, too.
You may also be interested in...
FDA Clears GSK’s Requip XL For Parkinson’s
Once-daily version is designed to battle generic competitors.
FDA Clears GSK’s Requip XL For Parkinson’s
Once-daily version is designed to battle generic competitors.
Pivotal Trial For GSK/Xenoport’s Sustained-Release Restless Legs Drug Supports Efficacy
Sales of the drug could reach $958 million in 2013, analyst predicts, including RLS and neuropathic pain indications.